Literature DB >> 11751034

Effects of smoking abstinence on visuospatial working memory function in schizophrenia.

Tony P George1, Jennifer C Vessicchio, Angelo Termine, Deanna M Sahady, Cory A Head, W Thomas Pepper, Thomas R Kosten, Bruce E Wexler.   

Abstract

Schizophrenic patients have impairments in cognitive function, including deficits in visuospatial working memory (VSWM). VSWM is mediated, in part, by prefrontal cortical dopamine (DA) function, and dysregulation of prefrontal cortical DA systems may contribute to the pathophysiology of schizophrenia. Nicotine has complex effects on spatial working memory (SWM) in animal studies, with most studies demonstrating enhancement of SWM. Cigarette smoking is highly prevalent in schizophrenia, and these patients may smoke cigarettes to remediate cognitive deficits. The present study examined the effects of acute (<1 week) and prolonged (8-10 weeks) smoking abstinence on VSWM in schizophrenic (n = 23) and control (n = 29) nicotine-dependent cigarette smokers during placebo-controlled smoking cessation trials. Schizophrenic and control smoking patients had significant impairments in VSWM compared to non-smoking controls, after adjusting for differences in age, education and depressive symptoms. Schizophrenic smokers who quit smoking had further impairments in VSWM, and control quitters had improvements in VSWM. Abstinence-induced changes in VSWM varied as a function of gender in controls, but not in schizophrenics. These changes in VSWM appeared to be independent of study medications, and smoking abstinence did not significantly alter performance on the Stroop Color Word Test in either group. These results suggest that smoking abstinence differentially alters VSWM in schizophrenic vs. control smokers, and that cigarette smoking has beneficial effects on VSWM in schizophrenic, but not control, smokers.

Entities:  

Mesh:

Year:  2002        PMID: 11751034     DOI: 10.1016/S0893-133X(01)00296-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  70 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

2.  Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.

Authors:  Samantha L Rushforth; Thomas Steckler; Mohammed Shoaib
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

4.  Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia.

Authors:  Christopher G AhnAllen; Paul G Nestor; Martha E Shenton; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

5.  Effects of cigarette smoking and abstinence on Stroop task performance.

Authors:  Catherine P Domier; John R Monterosso; Arthur L Brody; Sara L Simon; Adrianna Mendrek; Richard Olmstead; Murray E Jarvik; Mark S Cohen; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2007-07-19       Impact factor: 4.530

Review 6.  Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine.

Authors:  Justin W Kenney; Thomas J Gould
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

7.  Diabetes is associated with lower global cognitive function in schizophrenia.

Authors:  Yoichiro Takayanagi; Nicola G Cascella; Akira Sawa; William W Eaton
Journal:  Schizophr Res       Date:  2012-09-29       Impact factor: 4.939

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

10.  Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.

Authors:  Taryn G Moss; Kristi A Sacco; Taryn M Allen; Andrea H Weinberger; Jennifer C Vessicchio; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-05-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.